Given the role of CSF-1R in immune cell recruitment to ALS-affected nerves, as well as CSF-1R inhibitors, gene therapy could be designed to downregulate or inhibit CSF-1R expression in Schwann cells, limiting immune cell infiltration and thus reducing neuroinflammation in peripheral nerves [208,211]. This evidence concerns the gene CSF1R and amyotrophic lateral sclerosis.